Key Facts

Invested since 2019
Based in International

About the company

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York.

The portfolio is based on profound knowledge and expertise in liver disease, unique patient-derived model systems and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which show consistent compelling efficacy and safety in patient-derived cell and animal models.

Furthermore, Alentis has a proprietary discovery platform enabling fast-track discovery and development of compounds and targets that are relevant in the pathology of late stage liver disease and carcinogenesis.

Do you want to

know more about this company?

Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

Alentis in the news

Zum Artikel

News

13. April 2023

Alentis Therapeutics closes $105 million Series C funding to advance transformational medicines for Claudin-1

Zum Artikel

News

15. June 2021

Alentis Therapeutics Raises USD 67 Million in Series B Financing

Zum Artikel

News

30. April 2019

ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer

More startups from Life Sciences